Clinical Trial Update: Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravaginal prasterone (DHEA) for genitourinary syndrome of menopause in postmenopausal women with a history of breast cancer. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Genitourinary Syndrome of Menopause

Drugs mentioned

• Intrarosa (prasterone)

Snippet

Sponsor: European Institute of Oncology | Conditions: Women With Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING